Clorox (NYSE:CLX) 주식

Clorox

Since its start more than 100 years ago, Clorox has expanded to operate in a variety of consumer products categories, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. More than 80% of Clorox's sales come from its home turf.

The Decline

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

NXPI

TBNK

월요일(3일) 아침 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다. 월요일 주목해야 할 주식: 타이슨 푸드, 크로락스, 테리토리얼 뱅코프, 패브리넷 및 NXP 세미컨덕터

월요일 주목해야 할 주식: 타이슨 푸드, 크로락스, 테리토리얼 뱅코프, 패브리넷 및 NXP 세미

Market,Sentiment,,Fear,And,Greed,Index,,Emotional,On,Stock,Market

Long Ideas

AAPL

CNN 머니 공포·탐욕 지수는 전체적인 시장 심리가 하락했음을 보여 주었고, 금요일에 &#34;중립&#34; 영역에 머물렀다. 미국 증시는 금요일에 하락 마감하였으며, 다우존스 지수는 트럼프 행정부가 캐나다, 멕시코, 중국산 수입품에 대해 새로운 관세를 부과하면서 무역 긴장이 고조된 이후 300포인트 이상 하락했다. 

트럼프 관세 부과 속 다우 지수 300p 이상 하락: 공포·탐욕 지수는 &#39;중립&#39; 영역에

Wall-Street-ai7-1

Analyst Color

Equities

Large Cap

Mid Cap

Tech

ETFs

AMGN

AVGO

AZEK

DELL

Janus Henderson Group plc Ordinary Shares

KVYO

MNDY

NVDA

QGEN

SNOW

TOST

UPST

3분기 실적 시즌이 다가오면서, 골드만삭스는 투자자들이 재무 실적을 통해 수익을 올릴 수 있는 주요 주식 기회를 식별한 노트를 발표했다. 애널리스트 존 마샬(John Marshall)과 그의 팀은 목요일에 18개의 주식이 실적 상향 조정의 혜택을 받을 가능성이 있고, 7개의 주식은 하향 조정의 영향을 받을 가능성이 있다고 강조했다.

이번 실적 시즌에 매수할 주식 18개, 매도할 주식 7개: 골드만삭스는 올해를 &#39;주식 선택자의 해&#39;

Clorox Co

Calix Ltd

COLLEXIS HOLDINGS INC by Collexis Holdings, Inc.

UBS analyst Peter Grom maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and lowers the price target from $176 to $154.

Price Target

Analyst Ratings

UBS Maintains Neutral on Clorox, Lowers Price Target to $154

Wells Fargo analyst Chris Carey maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Equal-Weight and lowers the price target from $155 to $145.

Wells Fargo Maintains Equal-Weight on Clorox, Lowers Price Target to $145

JP Morgan analyst Andrea Teixeira maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and lowers the price target from $173 to $151.

JP Morgan Maintains Neutral on Clorox, Lowers Price Target to $151

Looking into the current session, Clorox Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) shares are trading at $139.18, after a 1.22% decrease. Over the past month, the stock decreased by 4.47%, but over the past year, it actually increased by 0.04%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1744383619_0.png" alt="Past Year Chart" />

<h3>Comparing Clorox P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 24.04 in the Household Products industry, Clorox Inc. has a higher P/E ratio of 38.39. Shareholders might be inclined to think that Clorox Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744383619_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

P/E Ratio Insights for Clorox

Wells Fargo analyst Chris Carey maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Equal-Weight and lowers the price target from $161 to $155.

Wells Fargo Maintains Equal-Weight on Clorox, Lowers Price Target to $155

Barclays analyst Lauren Lieberman maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Underweight and lowers the price target from $140 to $139.

Barclays Maintains Underweight on Clorox, Lowers Price Target to $139

The Can Manufacturers Institute (CMI) has raised concerns over the impact of newly enacted <a href="https://www.benzinga.com/markets/equities/25/03/44269301/trumps-25-tariffs-on-steel-and-aluminum-imports-take-effect-eu-retaliates-us-steel-nucor-century-aluminum-and-other-domestic-stocks-cheer">steel and aluminum tariffs</a>.
What Happened: The CMI warns that tariffs will have an inflationary influence on the domestic can industry. 
The Trump administration argues that these measures would protect domestic production and reduce reliance on foreign metals. But manufacturers say they will raise costs and harm competitiveness.
"While we support President Donald Trump's efforts to address unfair trade practices, tariffs on steel and aluminum will increase prices for canned foods and beverages," CMI's president Robet Budway <a href="https://www.cancentral.com/can-manufacturers-respond-to-trump-232-tariffs-steel-aluminum/">said</a> in a statement.
Per the Aluminum Association, Canada provides nearly two-thirds of the <a href="https://www.aluminum.org/news/us-aluminum-industry-responds-232-implementation-calls-certainty-tariff-landscape">domestically used aluminum</a>, while Mexico is the third-largest supplier. The new tariffs apply to all non-USMCA-compliant imports. Even compliant goods from Canada and Mexico will be subject to tariffs starting April 2. Additionally, China faces separate 20% tariffs on its aluminum exports to the U.S.
The U.S. can-making industry produces around 135 million cans annually, employing over 28,000 workers across 33 states. Nine domestic mill production lines have closed since the original 2018 tariffs on tin mill steel. That leaves only three operational facilities. CMI warns that domestic production cannot meet the demand, forcing manufacturers to rely on imports.
Numerous large companies rely on aluminum cans for manufacturing, particularly in the beverage, food, and aerosol industries. They include Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), Campbell Soup  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NYSE">CPB</a>), and Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>).
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44275216/bitcoin-to-defy-trump-tariffs-recession-fears-will-hit-200000-by-end-of-2025-standard-chartered">Bitcoin To Defy Trump Tariffs, Recession Fears, Will Hit $200,000 By End Of 2025: Standard Chartered</a>
Why It Matters: The situation will likely get worse for manufacturers, according to Japanese bank Nomura. 
The firm published a special report evaluating the effects of these tariffs. The firm estimated that the effective tariff rate on total U.S. imports will rise from 2.4% in 2024 to 10.1% in 2025 due to the expanded scope of trade restrictions. 
Furthermore, it warned about the retaliatory measures from key trading partners, particularly the European Union, which are likely in the coming months.
Nomura anticipates that while the current tariffs are 25%, the cumulative tariff rate on targeted steel and aluminum products could climb as high as 35% once additional country-specific penalties are layered. This would further strain industries reliant on these materials, including can manufacturing.
To prevent this outcome, CMI has called for targeted tariff relief to ensure the competitiveness of U.S.-made canned goods.
"Aluminum and steel tariffs place price pressures on American-produced goods by artificially and dramatically increasing the cost of critical production materials, making U.S.-made food less competitive against foreign products. We are calling on President Trump to provide targeted tariff relief, ensuring steel and aluminum cans and the products packaged in those cans continue to be ‘Made in America.'"
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44325928/gold-smashes-through-3000-mark-as-markets-brace-for-turbulence-and-fed-signals">Gold Breaches $3,000 Mark On Market Turbulence And Fed Signals</a></li>
</ul>
Image: Shutterstock

Government

Regulations

Commodities

Politics

Legal

Can Manufacturers Warn About Tariffs, Ask For Targeted Relief

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird raised Mercury Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>) price target from $37 to $58. Baird analyst Peter Arment upgraded the stock from Neutral to Outperform. Mercury Systems shares closed at $42.09 on Tuesday. <a href="https://www.benzinga.com/quote/MRCY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho raised the price target for Hilton Worldwide Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) from $243 to $263. Mizuho analyst Ben Chaiken downgraded the stock from Outperform to Neutral. Hilton Worldwide shares closed at $258.74 on Tuesday. <a href="https://www.benzinga.com/quote/HLT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson cut The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) price target from $171 to $169. DA Davidson analyst Linda Bolton Weiser maintained a Neutral rating. Clorox shares closed at $148.21 on Tuesday. <a href="https://www.benzinga.com/quote/CLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham raised the price target for Silicon Laboratories Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) from $140 to $150. Needham analyst Quinn Bolton maintained a Buy rating. Silicon Laboratories shares closed at $136.60 on Tuesday. <a href="https://www.benzinga.com/quote/SLAB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stephens &amp; Co. cut the price target for Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) from $61 to $60. Stephens &amp; Co. analyst Jim Salera maintained an Equal-Weight rating. Chipotle shares closed at $59.02 on Tuesday. <a href="https://www.benzinga.com/quote/CMG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan raised Janus Henderson Group plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>) price target from $44 to $53. JP Morgan analyst Kenneth Worthington upgraded the stock from Neutral to Overweight. Janus Henderson shares settled at $44.02 on Tuesday. <a href="https://www.benzinga.com/quote/JHG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup raised Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) price target from $47 to $57. Citigroup analyst Filippo Falorni upgraded the stock from Sell to Neutral. Molson Coors shares closed at $52.95 on Tuesday. <a href="https://www.benzinga.com/quote/TAP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) price target from $15 to $11. Wells Fargo analyst Ken Gawrelski downgraded the stock from Overweight to Equal-Weight. Snap shares closed at $11.60 on Tuesday.  <a href="https://www.benzinga.com/quote/SNAP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc cut the price target for Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) from $150 to $140. Keybanc analyst John Vinh maintained an Overweight rating. AMD shares settled at $119.50 on Tuesday. <a href="https://www.benzinga.com/quote/AMD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity raised Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) price target from $650 to $700. Canaccord Genuity analyst Maria Ripps maintained a Buy rating. Spotify shares closed at $621.77 on Tuesday. <a href="https://www.benzinga.com/quote/SPOT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>

MRCY

SLAB

SNAP

SPOT

Spotify To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Wednesday

Barclays analyst Lauren Lieberman maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Underweight and raises the price target from $130 to $140.

Barclays Maintains Underweight on Clorox, Raises Price Target to $140

DA Davidson analyst Linda Bolton Weiser maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and lowers the price target from $171 to $169.

DA Davidson Maintains Neutral on Clorox, Lowers Price Target to $169

WIIM

Clorox shares are trading lower following Q2 financial results.

Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) reported better-than-expected second-quarter financial results <a href="https://www.benzinga.com/quote/CLX/earnings">Monday after the bell</a>.
Clorox reported fiscal second-quarter revenue of $1.69 billion, beating the consensus estimate of $1.63 billion, according to Benzinga Pro. The household consumer products company reported adjusted earnings of $1.55 per share, beating analyst estimates of $1.41 per share.
"We achieved better-than-expected results across sales, margin and EPS in the second quarter due to our strong demand creation plans, which also supported our share growth," said Linda Rendle, chair and CEO of Clorox. "We are further advancing our transformation as we embark upon a significant milestone with our Enterprise Resource Planning transition in the U.S., resulting in our updated outlook. I am confident that we are taking the right actions to deliver strong financial performance and long-term, profitable growth."
Clorox raised its full-year earnings forecast from a range of $6.65 to $6.90 per share to a new range of $6.95 to $7.35 per share versus estimates of $6.84 per share. The company also guided for 2025 net sales in a range of down 1% to up 2%.
Clorox shares fell 6.6% to trade at $149.19 on Tuesday.
These analysts made changes to their price targets on Clorox following earnings announcement.
<ul>
<li>Wells Fargo analyst Chris Carey maintained Clorox with an Equal-Weight and raised the price target from $157 to $161.</li>
<li>JP Morgan analyst Andrea Teixeira maintained Clorox with a Neutral and raised the price target from $171 to $173.</li>
</ul>
Considering buying CLX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04132432/image-28-1024x574.png" alt="" class="wp-image-765442" style="width:513px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04132432/image-28-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04132432/image-28-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04132432/image-28-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04132432/image-28.png 1116w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43463896/mcdonalds-to-290-here-are-10-top-analyst-forecasts-for-tuesday">McDonald&#8217;s To $290? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Clorox Analysts Boost Their Forecasts Following Upbeat Earnings

JP Morgan analyst Andrea Teixeira maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Neutral and raises the price target from $171 to $173.

JP Morgan Maintains Neutral on Clorox, Raises Price Target to $173

Wells Fargo analyst Chris Carey maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Equal-Weight and raises the price target from $157 to $161.

Wells Fargo Maintains Equal-Weight on Clorox, Raises Price Target to $161

Clorox Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) <a href="https://www.benzinga.com/news/earnings/25/02/43450398/clorox-stock-slides-on-q2-earnings">second-quarter</a> earnings and revenue exceeded expectations, however, its net sales declined 15% annually. The management reinstated confidence in its fourth-quarter forecast expecting mid-to-high-single-digit growth in organic sales driven by the Enterprise Resource Planning (ERP) implementation.
What Happened: ERP refers to a software system upgrade that Clorox is implementing to modernize its core business processes, including supply chain, finance, and other operational areas. The transition is expected to be completed in phases over six months.
During its earnings call the company CEO Linda Rendle said, &#8220;ERP transition is a very important step in our digital transformation, continuing to ensure that we have data and can move at the right speed with the right capabilities to enable the growth and productivity that we&#8217;re driving.&#8221;
While the company guided its third-quarter organic sales to be up low-single digits, with an impact from divestitures and forex, CFO Kevin Jacobsen said, &#8220;The ERP transition will add 1 to 2 points of growth over the course of the year, it&#8217;s all going to happen in Q4.&#8221;
See Also: <a href="https://www.benzinga.com/news/events/25/02/43455326/illumina-stock-tumbles-nearly-5-overnight-on-robinhood-as-china-adds-ilmn-calvin-klein-owner-pvh-to-unreliable-entities-list-amid-trade-war-with-us">Illumina Stock Tumbles Nearly 5% Overnight On Robinhood As China Adds ILMN, Calvin Klein Owner PVH To &#8216;Unreliable Entities List&#8217; Amid Trade War With US</a>
Why It Matters: Clorox exceeded analysts&#8217; expectations, reporting revenue of $1.69 billion and adjusted earnings of $1.55 per share. Despite a 15% decline in year-over-year net sales, the company improved its gross margin to 43.8% and increased operating cash flow to $401 million.
Clorox anticipates being at the higher end of its 11-13% free cash flow target as a percentage of sales before the ERP impact. The ERP implementation will likely bring it closer to the low end of the range due to inventory build and pre-paying suppliers.
Price Action: Shares of Clorox rose 0.69% to end Monday at $159.78 apiece. The exchange-traded fund tracking the S&amp;P 500 index, SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) declined 0.67% to $597.77 on Monday.
The average price target among 22 analysts <a href="https://www.benzinga.com/quote/CLX/analyst-ratings">tracked by Benzinga</a> is $151.4 with a ‘sell' rating. The estimates range from $120 to $187 apiece. Recent ratings from RBC Capital, Barclays, and JP Morgan suggest a $150.33 target, implying a potential downside of 3.34%.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/CLX/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="381" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04044618/CLX-ANR-1024x381.png" alt="" class="wp-image-764409" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04044618/CLX-ANR-1024x381.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04044618/CLX-ANR-300x112.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04044618/CLX-ANR-768x285.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04044618/CLX-ANR.png 1060w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/43454291/winner-winner-chicken-dinner-tyson-foods-q1-beat-showcases-improved-execution-in-poultry-says-ceo" target="_blank" rel="noreferrer noopener">Winner Winner, Chicken Dinner: Tyson Foods Q1 Beat Showcases ‘Improved Execution' In Poultry, Says CEO</a></li>
</ul>
Photo courtesy: Shutterstock

Market Summary

Clorox Beats Expectations Despite 15% Sales Drop, CEO Stays Confident In Q4 Growth

Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) reported second-quarter financial results Monday after the bell. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/02/n43448785/clorox-reports-q2-fiscal-year-2025-results-updates-outlook">of the report</a>.
Q2 Earnings: Clorox reported fiscal second-quarter revenue of $1.69 billion, beating the consensus estimate of $1.63 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The household consumer products company reported adjusted earnings of $1.55 per share, beating analyst estimates of $1.41 per share.
Clorox said net sales decreased 15% on a year-over-year basis. Health and Wellness sales fell 13%, Household sales decreased 11%, Lifestyle sales were down 16% and International sales fell 12%. 
Gross margin increased 30 basis points to&nbsp;43.8%, up from&nbsp;43.5%&nbsp;in the prior year&#8217;s quarter. Net cash provided by operations year-to-date came in at $401 million, up from $173 million year-over-year. 
Clorox ended the period with $290 million of cash and cash equivalents. 
&#8220;We achieved better-than-expected results across sales, margin and EPS in the&nbsp;second quarter&nbsp;due to our strong demand creation plans, which also supported our share growth,&#8221; said&nbsp;Linda Rendle, chair and CEO of Clorox.
&#8220;We are further advancing our transformation as we embark upon a significant milestone with our Enterprise Resource Planning transition in the U.S., resulting in our updated outlook. I am confident that we are taking the right actions to deliver strong financial performance and long-term, profitable growth.&#8221;
Outlook: Clorox raised its full-year earnings forecast from a range of $6.65 to $6.90 per share to a new range of $6.95 to $7.35 per share versus estimates of $6.84 per share. The company also guided for 2025 net sales in a range of down 1% to up 2%. 
CLX Price Action: <a href="http://benzinga.com/quote/clx">Clorox shares</a> were down 2.28% after-hours, trading at $155.13 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43449997/nxp-semiconductors-reports-better-than-expected-q4-results-details">NXP Semiconductors Reports Better-Than-Expected Q4 Results: Details</a></li>
</ul>
Photo: Shutterstock.
&nbsp;

Guidance

After-Hours Center

Movers

Clorox Stock Slides On Q2 Earnings

Clorox Says Operating Environment Remains Challenging; Closely Watching Additional Risks In Inflation And Tariffs

Fiscal Year 2025 Outlook
This fiscal year 2025 outlook does not include any potential impact from tariffs.
The company is&nbsp;updating the following elements of its fiscal year 2025 outlook:
<ul>
<li>The company now expects net sales to be down 1% to up 2%, including 1 to 2 points of benefit from incremental shipments related to the Enterprise Resource Planning (ERP) transition, which is expected to reverse in the front half of the next fiscal year. Organic sales are now expected to be up 4% to up 7%, excluding about 2 points of negative impact from the divestiture of the company's business in Argentina and about 3 points of negative impact from the divestiture of the VMS business. Excluding the incremental shipments related to the ERP transition, the company continues to expect organic sales to be up 3% to 5%.</li>
<li>Gross margin is now expected to be up 125 to 150 basis points, primarily due to the benefits of holistic margin management efforts, partially offset by cost inflation and higher trade promotion spending. This compares to the previous expectation of 100 to 150 basis points.</li>
<li>The company's effective tax rate is now expected to be about 26%. Excluding the impact of the VMS sale, the company expects its fiscal year adjusted effective tax rate to be about 23%.</li>
<li>Fiscal year diluted EPS is now expected to be between $5.52 and $5.92 versus previously $5.17 and $5.42, a year over year increase of 145% to 163%, respectively, reflecting the lapping of several one-time charges recorded in the year-ago period. This includes the profit from incremental shipments related to the ERP transition of 25 cents to 45 cents, which is expected to reverse in the front half of fiscal year 2026.</li>
<li>Adjusted EPS is now expected to be between $6.95 and $7.35 compared to the previous estimate of $6.65 and $6.90, a year over year increase of 13% to 19%, respectively. The main change is to reflect a 25 to 45 cent net benefit from the expected incremental shipments related to the company's ERP transition. Aside from this change, adjusted EPS also assumes lower input costs and a lower tax rate as compared to the previous outlook. Adjusted EPS excludes about 70 cents of expense from long-term strategic investments in digital capabilities and productivity enhancements, a 94 cent charge in the first quarter from the loss on sale related to the divestiture of the VMS business, and a 21 cent benefit from cyberattack insurance recoveries in the first half of this fiscal year.</li>
</ul>
The company is confirming the following elements of its fiscal year 2025 outlook:
<ul>
<li>Selling and administrative expenses continue to be expected to be between 15% to 16% of net sales, which includes about 150 basis points of impact from the company's strategic investments in digital capabilities and productivity enhancements.</li>
<li>Advertising and sales promotion spending is still expected to be 11% to 11.5% of net sales, reflecting the company's ongoing commitment to invest behind its brands.</li>
</ul>
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2" rowspan="1">___________________</td>
</tr>
<tr>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1">Organic sales growth / (decrease) and adjusted EPS are non-GAAP measures. See Non-GAAP Financial Information at the end of this press release for&nbsp;reconciliations to the most comparable GAAP measures.</td>
</tr>
<tr>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1">Adjusted&nbsp;EBIT is a non-GAAP measure. See Non-GAAP Financial Information at the end of this press release for reconciliations to the most comparable GAAP measures.</td>
</tr>
</tbody>
</table>
</figure>

The Clorox Company Raises FY25 EPS From $6.65-$6.90 To $6.95-$7.35 Vs $6.84 Est.; Net Sales To Be Down 1% To Up 2%

General

Clorox shares are trading higher following better-than-expected Q2 financial results.

Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) reported quarterly earnings of $1.55 per share which beat the analyst consensus estimate of $1.41 by 9.93 percent. This is a 28.24 percent decrease over earnings of $2.16 per share from the same period last year. The company reported quarterly sales of $1.69 billion which beat the analyst consensus estimate of $1.63 billion by 3.61 percent. This is a 15.28 percent decrease over sales of $1.99 billion the same period last year.

Comments

Clorox

뉴스

파트너 / 기고자

벤징가 글로벌